1.Ortayli N, Ringheim K, Collins L, Sladden T: Sexually transmitted infections: progress and challenges since the 1994 International Conference on Population and Development (ICPD). Contraception 2014, 90(6, Supplement):S22-S31.
2.Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM: Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012. PLoS One 2015, 10(1):e114989.
3.World Health Organization. Global hepatitis report [http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence = 1]. Accessed August 30, 2019.
4.Montenegro RA, Stephens C: Indigenous health in Latin America and the Caribbean. Lancet 2006, 367(9525):1859–1869.
5.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136(5):E359–386.
6.Pardo I. Guía de tamizaje de cancer de cuello uterino y mama [https://www.minsalud.gob.bo/images/Documentacion/dgss/Area_Continuo/LIBRO%20GUIA%20TAMIZAJE.pdf]. Accessed September 2019.
7.Dzuba IG, Calderon R, Bliesner S, Luciani S, Amado F, Jacob M: A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. Rev Panam Salud Publica 2005, 18(1):53–63.
8.Parana R, Almeida D: HBV epidemiology in Latin America. J Clin Virol 2005, 34 Suppl 1:S130–133.
9.Ropero Álvarez AM, Pérez-Vilar S, Pacis-Tirso C, Contreras M, El Omeiri N, Ruiz-Matus C, Velandia-González M: Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas. BMC Public Health 2017, 17(1):325.
10.Gomez-Dávila C. HOY HABLAMOS DEL SIDA [https://www.idhbolivia.org/images/noticias/2018/DATOSVIHSIDA2017.pdf]. Accessed August 2019.
11.Terán Calderón C, Gorena Urizar D, González Blázquez C, Alejos Ferreras B, Ramírez Rubio O, Bolumar Montrull F, Ortiz Rivera M, del Amo Valero J: Knowledge, attitudes and practices on HIV/AIDS and prevalence of HIV in the general population of Sucre, Bolivia. The Brazilian Journal of Infectious Diseases 2015, 19(4):369–375.
12.(CIPTA) CIdPT. Plan de gestion territorial indígena del pueblo TACANA 2015–2025 [https://searchworks.stanford.edu/view/11347692]. Accessed September, 2019.
13.Gruner N, Stambouli O, Ross RS: Dried blood spots—preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp 2015(97).
14.Kania D, Bekale AM, Nagot N, Mondain AM, Ottomani L, Meda N, Traore M, Ouedraogo JB, Ducos J, Van de Perre P et al: Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa. Clin Microbiol Infect 2013, 19(12):E533–541.
15.Gustavsson I, Sanner K, Lindell M, Strand A, Olovsson M, Wikstrom I, Wilander E, Gyllensten U: Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge. J Clin Virol 2011, 51(4):255–258.
16.Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J: Performance of Focus ELISA tests for herpes simplex virus type 1 (HSV–1) and HSV–2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004, 10(6):530–536.
17.García-Cisneros S, Sánchez-Alemán MÁ, Conde-Glez CJ, Lara-Zaragoza SJ, Herrera-Ortiz A, Plett-Torres T, Olamendi-Portugal M: Performance of ELISA and Western blot to detect antibodies against HSV–2 using dried blood spots. Journal of Infection and Public Health 2019, 12(2):224–228.
18.Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA: Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. Clin Vaccine Immunol 2006, 13(6):633–639.
19.Lindh M, Gorander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W: Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol 2007, 40(4):321–324.
20.Domercant JW, Jean Louis F, Hulland E, Griswold M, Andre-Alboth J, Ye T, Marston BJ: Seroprevalence of Herpes Simplex Virus type–2 (HSV–2) among pregnant women who participated in a national HIV surveillance activity in Haiti. BMC Infect Dis 2017, 17(1):577–577.
21.Rodriguez A, Castle P, Smith J, Bratti C, Hildesheim A, Schiffman M, Viscidi R, Burk R, Ashley R, Castellsague X et al: A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Sex Transm Infect 2003, 79(6):460–465.
22.Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, Gamieldien H, Ngcapu S, Johnson L, Lauffenburger DA et al: Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. Sex Transm Infect 2016, 92(3):186–193.
23.Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, Faillace T, Uusküla A, Nygård-Kibur M, Ramalingam S et al: Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect 2003, 79(4):286.
24.Brazzale AG, Russell DB, Cunningham AL, Taylor J, McBride WJ: Seroprevalence of herpes simplex virus type 1 and type 2 among the Indigenous population of Cape York, Far North Queensland, Australia. Sexual health 2010, 7(4):453–459.
25.Daniels B, Wand H, Ramjee G: Prevalence of Herpes Simplex Virus 2 (HSV–2) infection and associated risk factors in a cohort of HIV negative women in Durban, South Africa. BMC Res Notes 2016, 9(1):1–8.
26.Stieglitz J, Blackwell AD, Quispe Gutierrez R, Cortez Linares E, Gurven M, Kaplan H: Modernization, Sexual Risk-Taking, and Gynecological Morbidity among Bolivian Forager-Horticulturalists. PLoS One 2012, 7(12):e50384.
27.Zunzunegui MV, King MC, Coria CF, Charlet J: Male influences on cervical cancer risk. Am J Epidemiol 1986, 123(2):302–307.
28.Grabowski MK, Gray RH, Makumbi F, Kagaayi J, Redd AD, Kigozi G, Reynolds SJ, Nalugoda F, Lutalo T, Wawer MJ et al: Use of injectable hormonal contraception and women’s risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda. The Lancet Global Health, 3(8):e478-e486.
29.Lema CH, Hurtado LV, Segurondo D, Romero F, Dulon A, Asturizaga D, Panoso W, Garcia G, Fujiyoshi T, Yashiki S et al: Human Papillomavirus Infection among Bolivian Amazonian Women. Asian Pac J Cancer Prev 2001, 2(2):135–141.
30.Terán Calderón C: Prevalencia y factores asociados a la infección por el virus del papiloma humano (VPH) y las lesiones causadas por el mismo en mujeres de 20 a 59 años en el municipio de Sucre, Bolivia Dialnet: Universidad de Alcalá 2014.
31.Allende G, Surriabre P, Cáceres L, Bellot D, Ovando N, Torrico A, Calle P, Ascarrunz C, Alexander S, Bossens M et al: Evaluation of the self-sampling for cervical cancer screening in Bolivia. BMC Public Health 2019, 19(1):80.
32.Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD: A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. The Journal of Infectious Diseases 2005, 191(11):1808–1816.
33.Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093–1101.
34.Ramqvist T, Du J, Lunden M, Ahrlund-Richter S, Ferreira J, Marions L, Sparen P, Andersson S, Dalianis T: Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15–23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 2011, 43(2):115–121.
35.Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow S-N, Apter D, Kitchener H et al: Cross-protective efficacy of HPV–16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 2012, 13(1):100–110.
36.Jaramillo CM, de La Hoz F, Porras A, di Filippo D, Choconta-Piraquive LA, Payares E, Montes N, Navas M-C: Characterization of hepatitis B virus in Amerindian children and mothers from Amazonas State, Colombia. PLoS One 2017, 12(10):e0181643.
37.Khan A, Tanaka Y, Saito H, Ebinuma H, Sekiguchi H, Iwama H, Wakabayashi G, Kamiya T, Kurbanov F, Elkady A et al: Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia. Virus Res 2008, 132(1):174–180.
38.Ministerio de Salud y Deportes, and ITS/VIH/SIDA PN. Prevalencia e incidencia de VIH/SIDA (estimaciones con el modelo epidemiológico del EPP-Spectrum) “Vigilancia Centinela” [https://www.minsalud.gob.bo/1531-presentan-resultados-de-vigilancia-centinela-sobre-transmision-materno-infantil-del-vih-y-sifilis]. Accessed September 2019.
39.Pereira GF, Sabido M, Caruso A, Oliveira SB, Mesquita F, Benzaken AS: HIV Prevalence among Pregnant Women in Brazil: A National Survey. Rev Bras Ginecol Obstet 2016, 38(8):391–398.